Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Adam Kibel, M.D.

Co-Author

This page shows the publications co-authored by Adam Kibel and Quoc-Dien Trinh.
Connection Strength

18.965
  1. Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncol Pract. 2021 05; 17(5):e654-e665.
    View in: PubMed
    Score: 0.242
  2. Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer? J Comp Eff Res. 2021 06; 10(9):733-741.
    View in: PubMed
    Score: 0.242
  3. Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. Minerva Urol Nephrol. 2021 06; 73(3):404-406.
    View in: PubMed
    Score: 0.241
  4. Reply by Authors. J Urol. 2021 05; 205(5):1274.
    View in: PubMed
    Score: 0.240
  5. Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? J Urol. 2021 May; 205(5):1263-1274.
    View in: PubMed
    Score: 0.238
  6. Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urol Oncol. 2021 02; 39(2):130.e17-130.e24.
    View in: PubMed
    Score: 0.236
  7. Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Netw Open. 2020 12 01; 3(12):e2030072.
    View in: PubMed
    Score: 0.236
  8. Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. Investig Clin Urol. 2021 Jan; 62(1):56-64.
    View in: PubMed
    Score: 0.235
  9. Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR Mhealth Uhealth. 2020 11 03; 8(11):e20224.
    View in: PubMed
    Score: 0.234
  10. Access denied: The relationship between patient insurance status and access to high-volume hospitals. Cancer. 2021 02 15; 127(4):577-585.
    View in: PubMed
    Score: 0.234
  11. Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. BMC Surg. 2020 Oct 14; 20(1):235.
    View in: PubMed
    Score: 0.233
  12. Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surg Endosc. 2021 04; 35(4):1644-1650.
    View in: PubMed
    Score: 0.225
  13. Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 12; 18(6):e651-e659.
    View in: PubMed
    Score: 0.225
  14. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.224
  15. Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. J Surg Oncol. 2020 Mar; 121(3):578-583.
    View in: PubMed
    Score: 0.221
  16. Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Netw Open. 2020 01 03; 3(1):e1919185.
    View in: PubMed
    Score: 0.221
  17. Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Ann Surg Oncol. 2020 Jun; 27(6):1929-1936.
    View in: PubMed
    Score: 0.220
  18. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.220
  19. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289.
    View in: PubMed
    Score: 0.219
  20. The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. Cancer. 2020 02 01; 126(3):496-505.
    View in: PubMed
    Score: 0.218
  21. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol. 2021 Feb; 4(1):66-72.
    View in: PubMed
    Score: 0.218
  22. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.216
  23. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87.
    View in: PubMed
    Score: 0.213
  24. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068.
    View in: PubMed
    Score: 0.213
  25. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021 Jan; 7(1):124-131.
    View in: PubMed
    Score: 0.213
  26. Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 05 03; 2(5):e194634.
    View in: PubMed
    Score: 0.211
  27. The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18.
    View in: PubMed
    Score: 0.211
  28. Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. J Oncol Pract. 2019 06; 15(6):e547-e559.
    View in: PubMed
    Score: 0.210
  29. Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? Prostate Cancer Prostatic Dis. 2019 12; 22(4):593-599.
    View in: PubMed
    Score: 0.210
  30. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.210
  31. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.210
  32. Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Netw Open. 2019 02 01; 2(2):e187633.
    View in: PubMed
    Score: 0.207
  33. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003.
    View in: PubMed
    Score: 0.207
  34. Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clin Genitourin Cancer. 2019 06; 17(3):e488-e493.
    View in: PubMed
    Score: 0.207
  35. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.207
  36. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.204
  37. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555.
    View in: PubMed
    Score: 0.204
  38. Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838.
    View in: PubMed
    Score: 0.203
  39. Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference? Eur Urol Oncol. 2019 07; 2(4):349-354.
    View in: PubMed
    Score: 0.202
  40. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.201
  41. Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018 Nov; 36(11):1767-1774.
    View in: PubMed
    Score: 0.199
  42. Contemporary trends in the utilisation of radical prostatectomy. BJU Int. 2018 11; 122(5):726-728.
    View in: PubMed
    Score: 0.198
  43. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.196
  44. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
    View in: PubMed
    Score: 0.194
  45. Reassessing the value of high-volume cancer care in the era of precision medicine. Cancer. 2018 04 01; 124(7):1319-1321.
    View in: PubMed
    Score: 0.194
  46. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018 06; 199(6):1417-1425.
    View in: PubMed
    Score: 0.194
  47. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.194
  48. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
    View in: PubMed
    Score: 0.192
  49. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urol Oncol. 2018 02; 36(2):78.e13-78.e19.
    View in: PubMed
    Score: 0.191
  50. Approach to the Patient with High-Risk Prostate Cancer. Urol Clin North Am. 2017 Nov; 44(4):635-645.
    View in: PubMed
    Score: 0.190
  51. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
    View in: PubMed
    Score: 0.188
  52. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
    View in: PubMed
    Score: 0.188
  53. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382.
    View in: PubMed
    Score: 0.187
  54. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.186
  55. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. J Urol. 2017 11; 198(5):1061-1068.
    View in: PubMed
    Score: 0.185
  56. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.183
  57. Assessing robot-assisted laparoscopic prostatectomy. Lancet. 2017 02 25; 389(10071):799.
    View in: PubMed
    Score: 0.181
  58. The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. Am J Surg. 2017 Nov; 214(5):871-883.
    View in: PubMed
    Score: 0.179
  59. Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. J Endourol. 2016 12; 30(12):1291-1295.
    View in: PubMed
    Score: 0.179
  60. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.177
  61. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
    View in: PubMed
    Score: 0.173
  62. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.172
  63. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.168
  64. Causes of hospital readmissions after urologic cancer surgery. Urol Oncol. 2016 May; 34(5):236.e1-11.
    View in: PubMed
    Score: 0.167
  65. Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program. Ann Surg. 2015 Dec; 262(6):955-64.
    View in: PubMed
    Score: 0.167
  66. Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. Eur Urol Focus. 2016 Apr; 2(1):3-9.
    View in: PubMed
    Score: 0.166
  67. The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011. World J Surg. 2015 Oct; 39(10):2376-85.
    View in: PubMed
    Score: 0.165
  68. Suicide and accidental deaths among patients with non-metastatic prostate cancer. BJU Int. 2016 Aug; 118(2):286-97.
    View in: PubMed
    Score: 0.164
  69. Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2015 Sep; 13(9):1131-8.
    View in: PubMed
    Score: 0.164
  70. Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urol Oncol. 2015 Dec; 33(12):503.e7-15.
    View in: PubMed
    Score: 0.164
  71. Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
    View in: PubMed
    Score: 0.163
  72. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int. 2016 08; 118(2):221-9.
    View in: PubMed
    Score: 0.162
  73. A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. J Endourol. 2015 Sep; 29(9):1052-8.
    View in: PubMed
    Score: 0.161
  74. An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int. 2015 Dec; 116(6):911-9.
    View in: PubMed
    Score: 0.161
  75. The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. J Surg Educ. 2015 Sep-Oct; 72(5):1018-25.
    View in: PubMed
    Score: 0.161
  76. Impact of smoking on perioperative outcomes after major surgery. Am J Surg. 2015 Aug; 210(2):221-229.e6.
    View in: PubMed
    Score: 0.160
  77. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015 Feb; 85(2):343-9.
    View in: PubMed
    Score: 0.157
  78. Effect of preoperative angina pectoris on cardiac outcomes in patients with previous myocardial infarction undergoing major noncardiac surgery (data from ACS-NSQIP). Am J Cardiol. 2015 Apr 15; 115(8):1080-4.
    View in: PubMed
    Score: 0.157
  79. Readmissions after major urologic cancer surgery. Can J Urol. 2014 Dec; 21(6):7537-46.
    View in: PubMed
    Score: 0.155
  80. Contemporary nationwide patterns of self-reported prostate-specific antigen screening. JAMA Intern Med. 2014 Nov; 174(11):1839-41.
    View in: PubMed
    Score: 0.155
  81. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan; 33(1):17.e9-17.e18.
    View in: PubMed
    Score: 0.154
  82. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol. 2015 Jul; 68(1):32-9.
    View in: PubMed
    Score: 0.154
  83. Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database. JAMA Surg. 2014 Oct; 149(10):1039-44.
    View in: PubMed
    Score: 0.154
  84. The impact of resident involvement in minimally-invasive urologic oncology procedures. Can Urol Assoc J. 2014 Sep; 8(9-10):334-40.
    View in: PubMed
    Score: 0.153
  85. Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J. 2014 Sep; 8(9-10):E681-7.
    View in: PubMed
    Score: 0.153
  86. Mental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014 Nov; 32(8):1333-40.
    View in: PubMed
    Score: 0.152
  87. Preventable mortality after common urological surgery: failing to rescue? BJU Int. 2015 Apr; 115(4):666-74.
    View in: PubMed
    Score: 0.152
  88. Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urol Oncol. 2014 Nov; 32(8):1259-66.
    View in: PubMed
    Score: 0.152
  89. Chronic kidney disease and perioperative outcomes in urological oncological surgery. Int J Urol. 2014 Dec; 21(12):1245-52.
    View in: PubMed
    Score: 0.151
  90. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014 May 10; 32(14):1419-26.
    View in: PubMed
    Score: 0.149
  91. Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol. 2014 Jul; 28(7):831-40.
    View in: PubMed
    Score: 0.148
  92. The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis. J Urol. 2014 Jun; 191(6):1678-84.
    View in: PubMed
    Score: 0.146
  93. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2021 Jun 01; 113(6):719-726.
    View in: PubMed
    Score: 0.061
  94. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021 07; 39(7):436.e1-436.e10.
    View in: PubMed
    Score: 0.060
  95. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87.
    View in: PubMed
    Score: 0.060
  96. The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer. 2021 May 01; 127(9):1387-1394.
    View in: PubMed
    Score: 0.059
  97. Delayed blood transfusion is associated with mortality following radical cystectomy. Scand J Urol. 2020 Aug; 54(4):290-296.
    View in: PubMed
    Score: 0.057
  98. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urol Oncol. 2020 03; 38(3):74.e13-74.e20.
    View in: PubMed
    Score: 0.055
  99. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol. 2020 Sep; 38(9):2227-2236.
    View in: PubMed
    Score: 0.055
  100. Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology. 2020 Jan; 135:44-49.
    View in: PubMed
    Score: 0.054
  101. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int. 2019 07; 124(1):40-46.
    View in: PubMed
    Score: 0.053
  102. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019 04 10; 37(11):923-931.
    View in: PubMed
    Score: 0.052
  103. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458.
    View in: PubMed
    Score: 0.052
  104. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019 Oct; 37(10):2059-2065.
    View in: PubMed
    Score: 0.051
  105. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol. 2019 03; 75(3):399-407.
    View in: PubMed
    Score: 0.051
  106. Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. Eur Urol Focus. 2020 01 15; 6(1):74-80.
    View in: PubMed
    Score: 0.051
  107. Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Can Urol Assoc J. 2019 Feb; 13(2):32-37.
    View in: PubMed
    Score: 0.050
  108. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 09; 21(3):364-372.
    View in: PubMed
    Score: 0.048
  109. Associations of specific postoperative complications with costs after radical cystectomy. BJU Int. 2018 03; 121(3):428-436.
    View in: PubMed
    Score: 0.048
  110. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
    View in: PubMed
    Score: 0.047
  111. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
    View in: PubMed
    Score: 0.045
  112. The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology. 2016 Aug; 94:70-6.
    View in: PubMed
    Score: 0.043
  113. Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urol Oncol. 2016 07; 34(7):293.e1-293.e10.
    View in: PubMed
    Score: 0.043
  114. The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. J Urol. 2016 Feb; 195(2):399-405.
    View in: PubMed
    Score: 0.041
  115. Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World J Urol. 2015 Dec; 33(12):2107-13.
    View in: PubMed
    Score: 0.040
  116. The impact of resident involvement in male one-stage anterior urethroplasties. Urology. 2015 Apr; 85(4):937-41.
    View in: PubMed
    Score: 0.040
  117. Urolithiasis and urinary tract infection among patients with inflammatory bowel disease: a review of US emergency department visits between 2006 and 2009. Urology. 2015 Apr; 85(4):764-70.
    View in: PubMed
    Score: 0.039
  118. Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015 May; 115(5):713-21.
    View in: PubMed
    Score: 0.039
  119. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.